Various neuroscience reagents and resources can be obtained by researchers, including human DNA, brain bank tissue and stem cell lines.
The NeuroBioBank, supported by the NIMH, NINDS, and NICHD was established in September 2013 as a national resource for investigators utilizing human post-mortem brain tissue and related biospecimens for their research to understand conditions of the nervous system. With specimens that span neurological, neuropsychiatric, and neurodevelopmental diseases and disorders, the NeuroBioBank serves as a central point of access to the world-class collections of our five network sites. In addition, the NeuroBioBank provides researchers with a wealth of resources to facilitate their research, including medical records and clinical data sets (when available) as well as access to quality metrics and SOPs used by each site.
The contracts for the NeuroBioBank Tissue Repositories (NBTRs) were awarded to the following sites:
Please read the press release: http://www.ninds.nih.gov/news_and_events/news_articles/pressrelease_neurobiobank_11272013.htm
For further information, the NINDS contact is:
Anna Taylor, Ph.D.
Health Science Specialist
For more information on the NIH program, please see: www.neurobiobank.nih.gov
Additional Information on Selected Brain Banks
The Human Brain and Spinal Fluid Resource Center was created to help provide specimens related to neuropsychiatric and neurological diseases and disorders. The Center is associated with the Veterans Administration of Greater Los Angeles and is supported jointly with NINDS, NIMH and the National Multiple Sclerosis Society. The Center collects, stores, and distributes the highest quality and quantity of pre- and post-mortem tissues and fluids: brains, spinal cords, cerebrospinal fluid, serum, blood cells and urine. In addition the Center can provide neurological tissue from subjects with neurological disorders as well as control tissues from family members or other donors for use in research toward identifying treatments and cures for neurological diseases.
Dr. Beth-Anne Sieber
Program Director, NINDS
The NINDS-supported Parkinson’s Disease Biomarkers Program, or PDBP, provides longitudinal human biospecimens and associated data collected from Parkinson's and control subjects for use in Parkinson's Disease Biomarkers discovery projects. Biospecimen types available include: plasma, serum, DNA, PAX-gene tube (RNA), and Cerebrospinal fluid (CSF). A core of standardized de-identified HIPAA-compliant longitudinal clinical data, based on clinical data elements is available for each unique individual as well. These are harmonized and based upon the NINDS Common Data Elements (CDEs):http://www.commondataelements.ninds.nih.gov/.
Researchers can view available data via the Data Management Resource (DMR). Investigators have the ability to query (and download) clinical data using the “Query” tool, request biospecimens from the “NINDS Biorepository Catalog” and order biospecimens via the “Order Manager” tool. Investigators gain access to the DMR by requesting an account (Request a PDBP DMR account). Once a signed Data Use Certification (DUC) is received, a requesting investigator will be granted access to the Query tool, NINDS Biorepository catalog and Order Manager. To obtain access to biospecimens, investigators are asked to provide a summary of their proposed biomarker research project and a power analysis to justify the number and types of biospecimens requested. The PDBP Biospecimen Resource Access Committee (BRAC) reviews the requests and the NINDS Repository Staff (see http://ccr.coriell.org/Sections/Collections/NINDS/?SsId=10) works with investigators whose requests are approved to assure receipt of the biospecimens. The specimens arrive masked, and will only be unmasked once resultant data are submitted to the PDBP Data Management Resource (DMR).
More information can be found at http://pdbp.ninds.nih.gov
Dr. Katrina Gwinn
Program Director, NINDS
The National NeuroAIDS Tissue Consortium (NNTC) collects, stores, and distributes samples of nervous tissue, cerebrospinal fluid, blood, and other tissue from HIV-infected individuals. The NNTC has been supported by NIMH and NINDS since 1998 and operates through a National Coordinating Office and four regional centers: the Texas NeuroAIDS Research Center; the California NeuroAIDS Tissue Network; the National Neurological AIDS Bank; and the Manhattan HIV Brain Bank. The mission of the NNTC is to provide high quality and well-characterized tissue samples from patients who died with HIV, including neuromedical and neuropsychiatric data gathered antemortem, to scientists studying the effects of HIV on the human brain. Since NNTC inception 2,158 participants have been enlisted for clinical evaluation and tissue donation. As of February 14, 2008, 723 central nervous system specimens from both HIV-infected and control subjects have been collected with an additional 1,450 blood samples available, 710 participates have at least three serial samples and 917 CSF samples available obtained from the NNTC patient cohort. NNTC encourages researchers to request tissues and/or clinical data for ancillary studies.
The aim of the NINDS Human Genetics Resource Center (also known as the NINDS Repository) is to store and distribute genetics samples, cell lines, and clinical data to aid in the discovery of genes involved in neurological disorders. The Repository is an NINDS-funded contract to the Coriell Institute for Medical Research that banks and distributes cell lines and DNA for neurological disease. The available high quality DNA is accompanied by excellent clinical data. The NINDS Repository aims to bank a large number of samples to generate the statistical power necessary to detect the moderate effects of a single susceptibility gene in complex genetic disorders. Currently the repository has samples with the following diagnoses: Parkinson's disease (~2500 available), cerebrovascular disease and stroke (~4200 available), epilepsy (~680 available), motor neuron disease (~2100 available), and Tourette syndrome (~ 124 available). The Repository also banks and distributes neurologically normal control samples (~ 4100 available) as well as family-based control samples (~ 1000 available). Finally, samples with known Mendelian mutations are also available. To date, more than 4000 NINDS Repository samples have SNP genotype and phenotype data publically available in dbGaP. We encourage both academic and industry-sponsored investigators to deposit or withdraw samples from the NINDS Repository. Current plans include the addition of Dystonia samples to the disease collection and fibroblast cultures from patients with known Mendelian mutations in Parkinson's disease and other neurological disorders.